Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs United Microelectronics Corp (UMC) Price & Performance

Eli Lilly And CoTrade
United Microelectronics CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs United Microelectronics Corp — how do they compare? Eli Lilly And Co trades at $1,220.55 (market cap $1.08T), while United Microelectronics Corp trades at $19.03 (market cap $47.81B). The key difference: Eli Lilly And Co is far larger — about 22.6× United Microelectronics Corp's market cap, and United Microelectronics Corp pays the higher dividend (2.12%). Which is the better fit depends on your goals.

LLYUMC
Market Cap
$1.08T$47.81B
Sector
HealthTechnology
52-Week High
$1.24K$28.02
52-Week Low
$639.43$6.58
Enterprise Value
$1.13T$44.93B
Dividend Yield
0.57%2.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

United Microelectronics Corp

UMC trades at $19.50, up 3.78% today, with neutral technical signals and strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 expectation. Recent announcements include fab expansions in Singapore and Taiwan to meet AI-driven demand, supported by growing silicon photonics production. Valuation metrics show a P/E of 18.55 and P/S of 6.02, with robust profitability margins including 32.75% net income margin.

Outlook remains positive with projected revenue growth to $250.7B in 2026 and net income rebound to $82.1B. Key risks include semiconductor cycle volatility and execution challenges from capacity expansion. Analyst consensus shows mixed sentiment with 26.7% buy ratings versus 20% sell recommendations, suggesting cautious optimism amid expansion initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About United Microelectronics Corp

Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.

Read more on UMC